Hikma Pharmaceuticals

Sustainability Report and Carbon Intensity Rankings

Is Hikma Pharmaceuticals doing their part?

Their DitchCarbon score is 48

Hikma Pharmaceuticals has a DitchCarbon Score of 48 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, suggesting there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing sustainability efforts.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Hikma Pharmaceuticals is part of the health and social services industry, which has a low carbon intensity ranking. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Hikma Pharmaceuticals operates in the United Kingdom, which has a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing the carbon footprint associated with their operations.
6.44%

...this company is doing 6.44% better in emissions than the industry average.

Founded in 1978, Hikma Pharmaceuticals is a renowned player in the global pharmaceutical industry, headquartered in London. The company specializes in the development, manufacturing, and marketing of a wide array of generic and in-licensed pharmaceutical products, focusing on both solid and injectable forms. With a strong foothold in the Middle East and North Africa, the United States, and Europe, Hikma is listed on the London Stock Exchange and is a member of the FTSE 100 Index.

emission intelligence's platform recommendations for Hikma Pharmaceuticals

Hikma Pharmaceuticals should set clear, science-informed targets for reducing their Scope 3 emissions and foster sustainable practices throughout their supply chain, while maintaining transparency in their reporting, which could potentially lower their emissions by 35%.

Good news, Hikma Pharmaceuticals has embraced SBTi commitments

Hikma Pharmaceuticals has committed to setting science-based targets to significantly reduce its greenhouse gas emissions from company operations, which include both direct emissions and indirect emissions from purchased energy. These targets align with the ambitious goal of limiting global warming to 1.5°C, reflecting the company’s dedication to environmental sustainability.
Participating

Webinar — Procurement emission data made simple

Trends and best practices in 2024. Navigate regulatory compliance and get the emissions intelligence you need, without surveys.

Case study — How Compleat's clients use our carbon data

Making Compleat’s customers climate heroes. Download the 19-page case study PDF.

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Looking for a specific company?

Search our company directory or contact us for custom data requests.